Us Anti Snoring Devices Snoring Surgery Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The North American anti-snoring devices and snoring surgery market covers a spectrum of medical products and clinical procedures aimed at reducing or eliminating airway obstruction during sleep, which manifests as snoring and can progress to obstructive sleep apnea. The region, led overwhelmingly by the United States, with meaningful contributions from Canada, represents the largest single geographic market globally, supported by a mature healthcare system, widespread sleep laboratory infrastructure, and relatively robust private and public insurance coverage. In 2025, the market is estimated at approximately $1.5 billion, encompassing both over-the-counter consumer products and professionally fitted or surgically delivered treatments administered through sleep clinics, dental sleep medicine practices, and otolaryngology departments.

• •The market encompasses CPAP and BiPAP machines, mandibular advancement devices, tongue-retaining devices, nasal dilators, and surgical procedures including UPPP, septoplasty, and hypoglossal nerve stimulation.
• •The United States drives the vast majority of North American market revenue, with Canada representing a smaller but steadily growing share due to similar demographic and healthcare trends.
• •Demand is fueled by the high prevalence of obstructive sleep apnea in the region, with an estimated 30 million Americans affected and millions more remaining undiagnosed.

The market's 7.76 percent annual growth rate is underpinned by several interrelated macro and microeconomic factors. Rising rates of obesity, a primary risk factor for obstructive sleep apnea, have expanded the addressable patient population across all age groups. Simultaneously, the aging of the North American population, with its attendant increase in upper airway collapsibility, has sustained and broadened demand. Improved public and clinical awareness of the cardiovascular, metabolic, and cognitive consequences of untreated sleep-disordered breathing has driven higher screening and diagnosis rates. Advances in at-home sleep testing technology have lowered barriers to diagnosis, while expanded insurance coverage for both devices and surgical procedures has made treatment financially accessible to a larger share of patients.

• •The U.S. Centers for Disease Control and Prevention reports that obesity prevalence among American adults exceeds 40 percent, and excess weight is the single most significant modifiable risk factor for obstructive sleep apnea.
• •Home sleep apnea testing, which uses portable monitoring devices rather than requiring an overnight stay at a sleep lab, has grown substantially since gaining broader clinical acceptance, reducing costs and improving patient convenience.
• •Medicare, Medicaid, and major private insurers in the United States provide coverage for CPAP therapy, oral appliance therapy under certain conditions, and select surgical procedures, sustaining consistent demand.

The North American market is commonly segmented by product type, distribution channel, and geography. Product-wise, the market divides into devices, including positive airway pressure machines, oral appliances fitted by dentists, nasal dilators and strips, and wearable position-adjustment devices, and surgical procedures performed by otolaryngologists and oral surgeons. Within the United States, the Northeast and Midwest typically account for the largest shares of revenue, reflecting higher population density, greater sleep clinic concentration, and more comprehensive insurance networks. Canada's market, while smaller in absolute terms, is growing in proportion as provincial health systems expand coverage for sleep apnea-related treatments. Mexico represents a nascent but emerging segment, with increasing clinical adoption of CPAP and oral appliance therapy in urban centers.

• •Positive airway pressure devices, CPAP, APAP, and BiPAP machines, remain the largest single product segment by revenue, though patient adherence challenges have spurred growth in alternative and adjunctive products.
• •Oral appliance therapy, delivered through mandibular advancement devices custom-fitted by dental sleep medicine practitioners, is the fastest-growing device segment, driven by patient preference for less cumbersome alternatives to CPAP.
• •Surgical procedures, including radiofrequency ablation, tonsillectomy, and implantable hypoglossal nerve stimulators such as Inspire therapy, account for a smaller but high-margin and growing share of the market.

What are the recent trends and outlook?

Several structural trends are reshaping the competitive and clinical landscape of the North American anti-snoring and sleep apnea market. Consumer demand for alternatives to CPAP, driven by reports of discomfort, claustrophobia, and inconsistent adherence, has accelerated development and adoption of oral appliances, nasal therapies, and minimally invasive surgical options. Digital health integration is advancing rapidly, with connected CPAP machines transmitting adherence data to cloud platforms accessible by clinicians, and wearable consumer devices incorporating sleep tracking and positional therapy. The FDA has continued to clear innovative products, including over-the-counter mandibular advancement devices and expanded indications for existing surgical technologies. Looking forward, the market is expected to sustain its roughly 7.76 percent growth trajectory through the late 2020s, supported by aging demographics, rising obesity prevalence, ongoing clinical research into novel neuromodulation and drug-based therapies, and persistent innovation in comfort-focused, patient-centric product design.

• •Over-the-counter mandibular advancement devices cleared by the FDA have introduced lower-cost alternatives to professionally fitted oral appliances, expanding access for patients with mild to moderate obstructive sleep apnea.
• •Telemedicine adoption during the 2020s has integrated remote patient monitoring and virtual sleep consultations into standard care pathways, reducing friction in both diagnosis and ongoing treatment management.
• •Emerging innovations, including targeted muscle reinnervation techniques, upper airway stimulators with improved battery life, and pharmaceutical adjuncts targeting upper airway muscle tone, are positioned to diversify the treatment landscape over the next five years.